Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole

References

• Meunier P. J. Hyperthyroidism and osteoporosis. Ann. Endocrinol. (Paris) 1995; 56: 57–9
   PubMedGoogle Scholar
• Ford H. C., Crooke M. J., Murphy C. E. Disturbances of calcium and magnesium metabolism occur in most hyperthyroid patients. Clin. Biochem. 1989; 22: 373–6
   PubMedGoogle Scholar
• Ross D. S. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994; 4: 319–26
   PubMed Web of Science ®Google Scholar
• Mosekilde L., Melsen F., Bagger J. P., Myhre-Jensen O., Sorensen N. S. Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol. (Copenh.) 1977; 85: 515–25
   PubMedGoogle Scholar
• Peerenboom H., Keck E., Kruskemper H. L., Strohmeyer G. The defect of intestinal calcium transport in hyperthyroidism and its response to therapy. J. Clin. Endocrinol. Metab. 1984; 59: 936–40
   PubMedGoogle Scholar
• Charles P., Pose J. W., Mosekilde L., Jensen F. T. Estimation of bone turnover evaluated by 47 Ca-kinetics: efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase and urinary hydroxy-proline excretion. J. Clin. Invest. 1985; 76: 2254–8
   PubMed Web of Science ®Google Scholar
• Eyre D. R. Editorial: New markers of bone resorption. J. Clin. Endocrinol. Metab. 1992; 74: 470A–C
   PubMed Web of Science ®Google Scholar
• Delmas P. D., Demiaux B., Malaval L., Chapuy M. C., Edouard C., Meunier P. J. Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia: comparison with bone histomorphometry. J. Clin. Invest. 1986; 77: 985–91
   PubMed Web of Science ®Google Scholar
• Stepan J. J., Prest J., Broulik P., Pacovsky V. Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1987; 64: 1079–82
   PubMedGoogle Scholar
• Merle B., Delmas P. D. Normal carboxylation of circulating osteocalcin (bone GLA-protein) in Paget's disease of bone. Bone Miner. 1990; 11: 237–45
   PubMedGoogle Scholar
• Garnero P., Vassy V., Bertholin A., Riou J. P., Delmas P. D. Markers of bone turnover in hyperthyroidism and the effects of treatment. J. Clin. Endocrinol. Metab. 1994; 78: 955–9
   Google Scholar
• De Menis E., Da Rin G., Roiter I., Legovini P., Foscolo G., Conte N. Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Horm. Res. 1992; 37: 217–20
   PubMedGoogle Scholar
• Diamond T., Vine J., Smart R., Butler P. Thyrotoxic bone disease in women: a potentially reversible disorder. Ann. Intern. Med. 1994; 120: 8–11
   PubMed Web of Science ®Google Scholar
• Mudde A. H., Houben A. J., Nieuwenhuij-zen-Kruseman A. C. Bone metabolism during antithyroid drug treatment of endogenous subclinical hyperthyroidism. Clin. Endocrinol. (Oxf.) 1994; 41: 421–4
   PubMed Web of Science ®Google Scholar
• Fraser S. A., Anderson J. B., Smith D. A., Wilson G. M. Osteoporosis and fractures following thyrotoxicosis. Lancet 1971; 1: 981–3
   PubMed Web of Science ®Google Scholar
• Toh H. S., Claunch B. C., Brown P. H. Effect of hyperthyroidism and its treatment on bone mineral content. Arch. Intern. Med. 1985; 145: 883–7
   PubMedGoogle Scholar
• Lalau J. D., Sebert J. L., Marie A., Fournier A., Quichaud J. Effect of thyrotoxicosis and its treatment on mineral and bone metabolism. J. Endocrinol. Invest. 1986; 9: 491–6
   PubMedGoogle Scholar
• Mundy G. R., Shapiro J. L., Bandelin J. G., Raisz L. G. Direct stimulation of bone resorption by thyroid hormones. J. Clin. Invest. 1976; 58: 529–34
   PubMed Web of Science ®Google Scholar
• Lee M. S., Kim S. Y., Lee M. C., Cho B. Y., Min H. K. Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J. Endocrinol. Invest. 1990; 70: 766–70
   Google Scholar
• Melsen F., Mosekilde L. Morphometry and dynamic studies of bone changes in hyperthyroidism. Acta Pathol. Microbiol. Scand. [Sec. A] 1977; 85: 141–50
   Google Scholar
• Eriksen E. F., Mosekilde L., Melsen F. Trabecular bone remodelling and bone balance in hyperthyroidism. Bone 1985; 6: 421–8
   PubMedGoogle Scholar
• Bayley T. A., Harrison J. E., McNeill K. G., Mernagh J. R. Effect of thyrotoxicosis and its treatment on bone mineral and muscle mass. J. Clin. Endocrinol. Metab. 1980; 50: 916–22
   Google Scholar
• Kojima N., Sakata S., Nakamura S., Nagai K., Miura K. Serum concentration of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis. J. Endocrinol. Invest. 1992; 15: 491–6
   PubMedGoogle Scholar
• Lukert B. P., Higgins J. G., Stoskopf M. M. Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J. Clin. Endocrinol. Metab. 1986; 62: 1056–8
   PubMed Web of Science ®Google Scholar
• Riggs B. L., Melton L. J. Involutional osteoporosis. N. Engl. J. Med. 1986; 314: 1676–86
   PubMed Web of Science ®Google Scholar
• Aitken J. M., Hart D. M., Anderson J. B., Lindsay R., Smith D. A. Osteoporosis after oophorectomy for non-malignant disease. Br. Med. J. 1973; 1: 325–8
   Google Scholar
• Kaddam I. M., Iqbal S. J., Holland S., Wong M., Manning D. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline : creatinine ratio in patients with Paget's disease of bone. Ann. Clin. Biochem. 1994; 31: 327–30
   PubMedGoogle Scholar
• Legovini P., De Menis E., Da Rin G., Roiter I., Breda F., Artuso V., Di Virgilio R., Conte N. Increased serum levels of carboxytermi-nal propeptide of type 1 collagen (PICP) in hyperthyroidism. Horm. Metab. Res. 1994; 26: 334–7
   PubMedGoogle Scholar
• Boonekamp P. M., Wee-Pals L. J. A., van Wijk-van Lennep M. M. P., Thesingh C. W., Bij-Voet O. L. M. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986; 1: 27–39
   PubMedGoogle Scholar
• Rodan G. A., Balena R. Bisphosphonates in the treatment of metabolic bone diseases. Ann. Med. 1993; 25: 373–8
   PubMed Web of Science ®Google Scholar
• O'Doherty D. P., Bickerstaff D. R., McCIoskey E. V., Hamdy N. A. T., Beneton M. N. C., Harris S., Mian M., Kanis J. A. Treatment of Paget's disease of bone with aminohydroxy-butylidene bisphosphonate.J. Bone Miner. Res. 1990; 5: 483–91
   PubMed Web of Science ®Google Scholar
• Reasner C. A., Stone M. D., Hosking D. J., Bal-Lah A., Mundy G. R. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J. Clin. Endocrinol. Metab. 1993; 77: 1067–71
   PubMed Web of Science ®Google Scholar
• Rosen H. N., Moses A. C., Gundherg C., Kung V. T., Seyedin S. M., Chen T., Holick M., Greenspan S. L. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J. Clin. Endocrinol. Metab. 1993; 77: 664–9
   PubMedGoogle Scholar
• Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D., Golub E., Rodan G. A. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 1991; 88: 2095–105
   PubMed Web of Science ®Google Scholar
• Adami S., Baroni M. C., Broggini M. C., Carra-Telli L., Caruso I., Gnessi L., Laurenzi M., Lom-Bardi A., Norbiato G., Ortolani S., Ricerca E., Romanini L., Subrizi S., Weinberg J., Yates A. J. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis Int. 1993; 3(Suppl. 3)S21–7
   Google Scholar
• Harris S. T., Gerts B. J., Genant H. K., Chesnut C. H. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women.J. Clin. Endocrinol. Metab. 1993; 76: 1399–406
   Google Scholar
• Kanis J. A., Gertz B. J., Singer F., Ortolani S. Rationale for the use of alendronate in osteoporosis. Osteoporosis Int. 1995; 5: 1–13
   PubMed Web of Science ®Google Scholar
• Liberman U. A., Weiss S. R., Broil J., Minne H. W., Quan H., Bell N. H., Rodriguez-Portales J., Downs R. W., Dequeker J., Favus M., Seeman E., Recker R. R., Capizzi T., San-Tora A. C., Lombardi A., Shah R. V., Hirsch L. J., Karpf D. B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 1995; 333: 1437–43
   PubMed Web of Science ®Google Scholar